10-K · July 27, 2026
Champions Oncology delivered FY2026 revenue growth to $59.425 million, led by a 17.6% increase in pharmacology services, but the earnings trajectory reversed as heavier R&D, commercial, G&A and outsourced-laboratory…
Earnings analysis · 10-Q
CSBR earnings analysis
Filed September 11, 2026 · Our reading of the company's report
The latest report
Champions Oncology reported $15.232 million of revenue and GAAP EPS of $(0.03), while oncology services margin improved to 51%. The filing confirms effective disclosure controls as of July 31, 2026, no material…
Read full summary
Champions Oncology reported $15.232 million of revenue and GAAP EPS of $(0.03), while oncology services margin improved to 51%. The filing confirms effective disclosure controls as of July 31, 2026, no material internal-control changes, and no pending litigation. No quantitative revenue or EPS guidance was provided, and management reported no material changes to the risk factors disclosed in the 2026 Annual Report.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.03
What stood out
-
Revenue reached $15.232 million
Revenue was $15.232 million and GAAP EPS was $(0.03) for the reported quarter. The filing does not provide a quantitative forward outlook.
-
Services margin improved to 51%
Oncology services margin was 51%, an improvement from the prior reported period’s 47% in the supplied quarterly history, indicating sequential margin recovery despite a GAAP loss.
-
Controls deemed effective
Management concluded that disclosure controls and procedures were effective as of July 31, 2026, at the reasonable-assurance level under Exchange Act Rule 13a-15(e).
-
No material control changes
Management reported no material changes in internal control over financial reporting during the fiscal quarter ended July 31, 2026.
-
No pending litigation disclosed
The company reported no litigation currently pending or contemplated against the company, its officers or directors, or its property.
What to watch
-
GAAP loss persists
GAAP profitability remained negative, with EPS of $(0.03) for the quarter. The filing does not disclose positive operating income or free cash flow for the period.
-
Macro and geopolitical exposure
The filing identifies inflation, higher interest rates, supply-chain disruptions, geopolitical instability, and pandemic-like events as potential adverse factors; it specifically states that the company cannot predict their likelihood, duration, or magnitude.
-
No new risk-factor mitigation
The company states that there have been no material changes to the risk factors in its 2026 Annual Report as of the filing date, so no new 10-Q-specific risk-factor mitigation is provided.
-
Control effectiveness is not absolute
Management notes that internal controls provide only reasonable assurance and that future-period effectiveness could deteriorate if conditions change or compliance declines.
Management's outlook
The filing provides no quantitative revenue or EPS outlook. Management states that additional risk disclosures may be made in future filings, but no operating guidance is provided.
Earlier filings 4
10-Q · March 12, 2026
Champions Oncology, Inc. reported Q3 results for the period ending January 31, 2026, with revenue of $17 million, a slight decline of 2.8% year-over-year. The company posted a diluted EPS of -$0.02, falling short of the…
10-Q · December 15, 2025
Champions Oncology reported revenue of $15.0 million for Q2 2025, marking a notable 11.5% increase compared to $13.5 million in Q2 2024, driven by improved bookings. However, the company experienced a decrease in…
10-Q · September 15, 2025
Champions Oncology, Inc. reported a revenue of $13.995 million for Q1 2025, slightly decreasing 0.5% from $14.061 million in Q1 2024. Despite a modest increase in expenses, the company managed to achieve positive…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.